

# John P Murad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7485867/publications.pdf>

Version: 2024-02-01

18  
papers

835  
citations

840119

11  
h-index

1058022

14  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021, 29, 2335-2349.	3.7	51
2	Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. <i>Nature Biomedical Engineering</i> , 2021, 5, 1348-1359.	11.6	74
3	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	140
4	Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2018, 24, 95-105.	3.2	220
5	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncotarget</i> , 2018, 7, e1380764.	2.1	111
6	Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2268.	2.2	80
7	Abstract 4981: Extracellular spacer and co-stimulatory domains define target sensitivity and persistence of CAR T cells for the treatment of PSCA+ bone metastatic prostate cancer. , 2017, , .		0
8	204. HER2-Specific Chimeric Antigen Receptor T Cells for the Treatment of Breast-to-Brain Metastasis. <i>Molecular Therapy</i> , 2016, 24, S79-S80.	3.7	2
9	Antigen-Specific Inhibition of High-Avidity T Cell Target Lysis by Low-Avidity T Cells via Trogocytosis. <i>Cell Reports</i> , 2014, 8, 871-882.	2.9	21
10	Thromboxane A <sub>2</sub> Receptor. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 248-259.	1.0	22
11	Characterization of the In Vivo Antiplatelet Activity of the Antihypertensive Agent Losartan. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 308-314.	1.0	12
12	Mouse transient receptor potential channel 6: Role in hemostasis and thrombogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 853-856.	1.0	32
13	A novel antibody targeting the ligand binding domain of the thromboxane A <sub>2</sub> receptor exhibits antithrombotic properties in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2012, 421, 456-461.	1.0	12
14	Aspirin: Pharmacology and Clinical Applications. <i>Thrombosis</i> , 2012, 2012, 1-15.	1.4	48
15	The C-terminal segment of the second extracellular loop of the thromboxane A <sub>2</sub> receptor plays an important role in platelet aggregation. <i>Biochemical Pharmacology</i> , 2012, 83, 88-96.	2.0	8
16	Transient Receptor Potential Channel 6: Role in Hemostasis and Thrombogenesis. <i>FASEB Journal</i> , 2012, 26, 1116.2.	0.2	0
17	A Novel Antithrombotic Agent Targeting the Human Thromboxane A <sub>2</sub> Receptor. <i>FASEB Journal</i> , 2012, 26, 1116.1.	0.2	0
18	The Transient Receptor-Potential Channel 6 Plays a Critical Role In Platelet Function. <i>Blood</i> , 2010, 116, 3201-3201.	0.6	0